Growth hormone therapy in achondroplasia.
The status of growth hormone (GH) secretion together with the effect of GH therapy was studied in six children with achondroplasia. One patient had impaired GH secretion, which may, in part, be due to obesity. The pre-GH-treatment height velocity was 3.8 +/- 0.7 cm/year, but this increased to 6.0 +/- 1.0 cm/year in the first year of treatment and to 4.4 +/- 0.6 cm/year in the second year. One patient who underwent GH therapy for 4 years showed good response in height velocity. A considerable variation was observed in response to GH therapy within the treated cases.
Nishi
Y
Y
Department of Pediatrics, Hiroshima Red Cross Hospital, Japan.
Kajiyama
M
M
Miyagawa
S
S
Fujiwara
M
M
Hamamoto
K
K
D000130:Achondroplasia / Q000150:complications / Q000188:drug therapy*; D001827:Body Height / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D005539:Foramen Magnum / Q000187:drug effects; D006128:Growth / Q000187:drug effects; D013006:Growth Hormone / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis; D008297:Male; D009765:Obesity / Q000209:etiology
D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone